CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published ahead of print on November 29, 2006
Clinical Journal of the American Society of Nephrology
© 2006 American Society of Nephrology
doi: 10.2215/CJN.01170905
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
CJN.01170905v1
2/1/89    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bradbury, B. D.
Right arrow Articles by Gillespie, B. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bradbury, B. D.
Right arrow Articles by Gillespie, B. W.
Related Collections
Right arrowRelated Article

Received September 29, 2005
Accepted on September 26, 2006

ORIGINAL ARTICLES

Predictors of Early Mortality among Incident US Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)

Brian D. Bradbury *1, Rachel B. Fissell {dagger}, Justin M. Albert {ddagger}, Mary S. Anthony *, Cathy W. Critchlow *, Ronald L. Pisoni {ddagger}, Friedrich K. Port {ddagger}, and Brenda W. Gillespie {sect}

*Department of Global Epidemiology, Amgen, Inc., Thousand Oaks, California; {dagger}Department of Internal Medicine, Veteran’s Affairs Medical Center, {ddagger}Dialysis Outcomes and Practice Patterns Study (DOPPS), University Renal Research and Education Association and {sect}Department of Biostatistics, University of Michigan, Ann Arbor, Michigan


1 To whom correspondence should be addressed. E-mail: bradbury{at}amgen.com.


   Abstract

Mortality risk among hemodialysis (HD) patients may be highest soon after initiation of HD. A period of elevated mortality risk was identified among US incident HD patients, and which patient characteristics predict death during this period and throughout the first year was examined using data from the Dialysis Outcomes and Practice Patterns Study (DOPPS; 1996 through 2004). A retrospective cohort study design was used to identify mortality risk factors. All patient information was collected at enrollment. Life-table analyses and discrete logistic regression were used to identify a period of elevated mortality risk. Cox regression was used to estimate adjusted hazard ratios (HR) measuring associations between patient characteristics and mortality and to examine whether these associations changed during the first year of HD. Among 4802 incident patients, risk for death was elevated during the first 120 d compared with 121 to 365 d (27.5 versus 21.9 deaths per 100 person-years; P = 0.002). Cause-specific mortality rates were higher in the first 120 d than in the subsequent 121 to 365 d for nearly all causes, with the greatest difference being for cardiovascular-related deaths. In addition, 20% of all deaths in the first 120 d occurred subsequent to withdrawal from dialysis. Most covariates were found to have consistent effects during the first year of HD: Older age, catheter vascular access, albumin <3.5, phosphorus <3.5, cancer, and congestive heart failure all were associated with elevated mortality. Pre-ESRD nephrology care was associated with a significantly lower risk for death before 120 d (HR 0.65; 95% confidence interval 0.51 to 0.83) but not in the subsequent 121- to 365-d period (HR 1.03; 95% confidence interval 0.83 to 1.27). This care was related to approximately 50% lower rates of both cardiac deaths and withdrawal from dialysis during the first 120 d. Mortality risk was highest in the first 120 d after HD initiation. Inadequate predialysis nephrology care was strongly associated with mortality during this period, highlighting the potential benefits of contact with a nephrologist at least 1 mo before HD initiation.


Related Article

Predialysis Nephrology Care Improves Dialysis Outcomes: Now What? Or Chapter Two
Thomas A. Golper
Clin. J. Am. Soc. Nephrol. 2007 2: 143-145. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
I-W. Wu, S.-Y. Wang, K.-H. Hsu, C.-C. Lee, C.-Y. Sun, C.-J. Tsai, and M.-S. Wu
Multidisciplinary predialysis education decreases the incidence of dialysis and reduces mortality--a controlled cohort study based on the NKF/DOQI guidelines
Nephrol. Dial. Transplant., November 1, 2009; 24(11): 3426 - 3433.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. K. Sigrist, A. Levin, L. Er, and C. W. McIntyre
Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification
Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3157 - 3162.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
C. Couchoud, M. Labeeuw, O. Moranne, V. Allot, V. Esnault, L. Frimat, B. Stengel, and for the French Renal Epidemiology and Information
A clinical score to predict 6-month prognosis in elderly patients starting dialysis for end-stage renal disease
Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1553 - 1561.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
W. M. McClellan, H. Wasse, A. C. McClellan, A. Kipp, L. A. Waller, and M. V. Rocco
Treatment Center and Geographic Variability in Pre-ESRD Care Associate with Increased Mortality
J. Am. Soc. Nephrol., May 1, 2009; 20(5): 1078 - 1085.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
B. D. Bradbury, M. D. Danese, M. Gleeson, and C. W. Critchlow
Effect of Epoetin Alfa Dose Changes on Hemoglobin and Mortality in Hemodialysis Patients with Hemoglobin Levels Persistently below 11 g/dL
Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 630 - 637.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
M. B. Patwardhan, K. Kawamoto, D. Lobach, U. D. Patel, and D. B. Matchar
Recommendations for a Clinical Decision Support for the Management of Individuals with Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol., February 1, 2009; 4(2): 273 - 283.
[Abstract] [Full Text] [PDF]


Home page
NDT PlusHome page
F. Carrera and M. Burnier
Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations
NDT Plus, January 1, 2009; 2(suppl_1): i9 - i17.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the American Society of Nephrology.